ASIT+TM products characteristics have been confirmed in two independent phase II and one phase III clinical trials in about 750 patients with grass pollen rhinitis:profile

  • low incidence of side effects

  • short course treatment over 3 weeks before the pollen season

  • induction of antibodies blocking allergic reactions already one week after the treatment

  • reduction of the reactivity to an allergen provocation test

  • significant reduction of symptoms and rescue medication use over placebo